Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 4/2016

Open Access 01-04-2016 | Review Article

Biomarkers in heart failure with preserved ejection fraction

Authors: W. C. Meijers, A. R. van der Velde, R. A. de Boer

Published in: Netherlands Heart Journal | Issue 4/2016

Login to get access

Abstract

Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preserved ejection fraction (HFpEF). As a result, there is a scarcity of data describing the levels, dynamics, clinical and biochemical correlates, and biology of biomarkers in patients suffering from HFpEF, whereas HFpEF is in fact a very frequent clinical entity. This article discusses the value of different biomarkers in HFpEF. We describe various aspects of natriuretic peptide measurements in HFpEF patients, with a focus on diagnosis, prognosis and the risk prediction of developing heart failure. Further, we will discuss several emerging biomarkers such as galectin-3 and suppression of tumorigenicity 2, and recently discovered ones such as growth differentiation factor-15 and syndecan-1.
Literature
1.
Boer RA de, Daniels LB, Maisel AS, Januzzi JL Jr. State of the Art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–69.CrossRefPubMed
2.
Januzzi JL Jr, Felker GM. Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail. 2013;1:213–5.CrossRefPubMed
3.
Veldhuisen DJ van, Ruilope LM, Maisel AS, Damman K. Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. Eur Heart J. 2015; pii:ehv588. [Epub ahead of print].
4.
Sargento L, Satendra M, Longo S, Lousada N, Palma dos Reis R. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol. 2013;36:677–82.CrossRefPubMed
5.
Oremus M, McKelvie R, Don-Wauchope A, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev. 2014;19:413–9.CrossRefPubMed
6.
Nordenskjold AM, Ahlstrom H, Eggers KM, Frobert O, Venge P, Lindahl B. Short- and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease. Clin Chim Acta. 2013;422:15–20.CrossRefPubMed
7.
8.
Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3–8.CrossRefPubMed
9.
10.
Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595–601.CrossRefPubMed
11.
Maisel AS, McCord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010–7.CrossRefPubMed
12.
Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J. 2004;148:895–902.CrossRefPubMed
13.
Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277–84.CrossRefPubMed
14.
Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742–8.CrossRefPubMed
15.
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMed
16.
McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571–9.CrossRefPubMed
17.
Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.CrossRefPubMedPubMedCentral
18.
Brouwers FP, Gilst WH van, Damman K, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail. 2014;7:723–31.CrossRefPubMed
19.
Seliger SL, Lemos J de, Neeland IJ, et al. Older Adults, “Malignant” Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study). JACC Heart Fail. 2015;3:445–55.CrossRefPubMed
20.
Mogelvang R, Goetze JP, Pedersen SA, et al. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. J Card Fail. 2009;15:489–95.CrossRefPubMed
21.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004;109:3176–81.CrossRefPubMed
22.
Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011;4:569–77.CrossRefPubMed
23.
Jhund PS, Anand IS, Komajda M, et al. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015;17:809–17.CrossRefPubMed
24.
Veldhuisen DJ van, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498–506.CrossRefPubMed
25.
Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274–84.CrossRefPubMed
26.
McKelvie RS, Komajda M, McMurray J, et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010;16:128–34.CrossRefPubMed
27.
Luchner A, Behrens G, Stritzke J, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail. 2013;15:859–67.CrossRefPubMed
28.
Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151:999–1005.CrossRefPubMed
29.
Meijers WC, Hoekstra T, Jaarsma T, Veldhuisen DJ van, Boer RA de. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24. DOI 10.1007/s12471-016-0816-8.
30.
Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327.CrossRefPubMed
31.
Boer RA de, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–8.CrossRefPubMedPubMedCentral
32.
Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013;169:177–82.CrossRefPubMed
33.
Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–91.CrossRefPubMed
34.
Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–23.CrossRefPubMed
35.
Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–77.CrossRefPubMed
36.
AbouEzzeddine OF, Haines P, Stevens S, et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail. 2015;3:245–52.CrossRefPubMedPubMedCentral
37.
Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem. 2011;57:874–82.CrossRefPubMed
38.
Frioes F, Lourenco P, Laszczynska O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. 2015;104:491–9.CrossRefPubMed
39.
Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259–67.CrossRefPubMedPubMedCentral
40.
Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247–59.CrossRefPubMed
41.
Yu CM, Cheung BM, Leung R, Wang Q, Lai WH, Lau CP. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart. 2001;86:155–60.CrossRefPubMedPubMedCentral
42.
Krum H, Elsik M, Schneider HG, et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011;4:561–8.CrossRefPubMed
43.
Tromp J, Pol A van der, Klip IT, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7:457–62.CrossRefPubMed
44.
Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129–37.CrossRefPubMedPubMedCentral
45.
Izumiya Y, Hanatani S, Kimura Y, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014;30:338–44.CrossRefPubMed
46.
Kempf T, Haehling S von, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054–60.CrossRefPubMed
47.
Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail. 2011;17:31–8.CrossRefPubMed
48.
Sanders-van Wijk S, Empel V van, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006–14.CrossRefPubMed
49.
Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009;29:1144–9.CrossRefPubMedPubMedCentral
50.
Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O. Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels. 2007;22:30–3.CrossRefPubMed
51.
Kleber ME, Koller L, Goliasch G, et al. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail. 2015;8:25–32.CrossRefPubMed
Metadata
Title
Biomarkers in heart failure with preserved ejection fraction
Authors
W. C. Meijers
A. R. van der Velde
R. A. de Boer
Publication date
01-04-2016
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 4/2016
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-016-0817-7

Other articles of this Issue 4/2016

Netherlands Heart Journal 4/2016 Go to the issue

Editor’s Comment

Heart failure with preserved ejection fraction: current status and challenges for the future

Rhythm Puzzle Answer

A stumbling block or a stepping stone?

Review Article

How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing

Heart Beat

‘Elevated’ hemidiaphragm due to a pericardial cyst

Original Article

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides

Erratum

Erratum to: Tachyarrhythmia in patients with congenital heart disease: inevitable destiny

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits